Printer Friendly

Scancell Holdings and Karolinska Institute extend collaboration.

M2 EQUITYBITES-August 9, 2018-Scancell Holdings and Karolinska Institute extend collaboration

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Scancell Holdings plc (LON: SCLP) has extended its collaboration with Karolinska Institute's rheumatology unit, Proactive Investors reported on Thursday.

The extension builds on a pre-existing relationship between the company and Sweden's world-leading medical research university and it will focus on broadening the applications for Scancell's Moditope platform.

One of the company's main drug candidates, MODI-1, utilises the Moditope technology.

MODI-1, which will initially be trialled in breast and ovarian cancer as well as sarcoma that is found in fat, muscle, bone and tendons, stimulates the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmstrom, discovered that citrullinated proteins, which are normally associated with arthritis, play an essential role in the process of controlling tumour growth. The expansion will help them to develop Moditope for use in cancer vaccines and as part of other cancer immunotherapy approaches.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 9, 2018
Words:191
Previous Article:Basilea Pharmaceutica initiates Phase 3 study of ceftobiprole in SAB.
Next Article:Volkswagen collaborates with Waze.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters